Clinical Trial Detail

NCT ID NCT02684461
Title Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST